Mirador® Xtra Естония - естонски - Adama

mirador® xtra

adama - suspensioonikontsentraat - asoksüstrobiin + tsüprokonasool - fungitsiidid

Mistral® 700 WG Естония - естонски - Adama

mistral® 700 wg

adama - vees dispergeeruvad graanulid - metribusiin - herbitsiidid

Mixin® Естония - естонски - Adama

mixin®

adama - suspo-emulsioon - florasulaam + fluroksüpüür - herbitsiidid

Seedron® Естония - естонски - Adama

seedron®

adama - suspensioonikontsentraat - fludioksoniil + tebukonasool - muud tooted

Sultan® Super Естония - естонски - Adama

sultan® super

adama - suspensioonikontsentraat - kvinmerak + metasakloor - herbitsiidid

Tomahawk® 200 EC Естония - естонски - Adama

tomahawk® 200 ec

adama - emulsioonikontsentraat - fluroksüpüür - herbitsiidid

Sugammadex Fresenius Kabi Европейски съюз - естонски - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskulaarne blokaad - kõik muud ravitoimingud - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Kimmtrak Европейски съюз - естонски - EMA (European Medicines Agency)

kimmtrak

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastilised ained - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

CABAZITAXEL TEVA infusioonilahuse kontsentraat Естония - естонски - Ravimiamet

cabazitaxel teva infusioonilahuse kontsentraat

teva b.v. - kabasitakseel - infusioonilahuse kontsentraat - 10mg 1ml 6ml 1tk

Tecvayli Европейски съюз - естонски - EMA (European Medicines Agency)

tecvayli

janssen-cilag international n.v. - teclistamab - mitu müeloomit - antineoplastilised ained - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.